The Bridge Device
Medication Isn't The Only Way To Change How The Brain Works.
Many experts believe that both the pain of detox and the fear of that pain are one of the greatest barriers to patient detoxification and rehabilitation. It’s clear that many patients quit before they can be moved to a medication-assisted treatment program.
A new alternative pain management treatment for withdrawal and other acute pain patients is the BRIDGE medical device, which offers acute pain patients a powerful alternative to suffering through medication-assisted detox. The BRIDGE works through neuro-stimulation and is an auricular peripheral nerve field stimulator that connects topically to the patient’s ear, blocking pain signals from getting through the brain.
Cleared by the Food & Drug Administration as a 510(K) device, the BRIDGE is minimally-invasive, easy to work with, has a proven clinical track record, and is poised to make a tremendous improvement to both detox and rehab protocols.
The BRIDGE device works for men and women, young and old, regardless of race. It typically takes 15 minutes for a qualified provider to fit it behind the patient’s ear and to correctly place the needle arrays at specific points on the earlobe. Once attached, the patient typically wears the BRIDGE detox for the 4-to-5-day period of greatest, most acute pain, usually a maximum of 96 to 120 hours.
At that point in the detox process, they are through the worst of the withdrawal pain and discomfort and the device can be safely removed.
While the device is attached and operating, the patient experiences gentle pulsations and decreased pain. In relation to treatment, patients report the process was comfortable and seemed to go quickly.
The most common treatments to aid opioid addiction detox and withdrawal are buprenophine, methadone and naltrexone. They all work by blocking or partially blocking the opioid receptors in the brain and are categorized as either “agonists” that activate opioid receptors, “partial agonists” that produce a smaller response, or “antagonists” that block the receptor and interfere with the rewarding effects of opioids in the brain.
Methadone is a slow-acting opioid agonist, while naltrexone is an opioid antagonist and buprenophine is a partial opioid agonist.